Abstract
The term “antibiotics” is a broadly used misnomer to designate antibacterial drugs. In a recent article, we have proposed to replace, e.g., the term “antibiotics” by “antibacterial drugs”, “antibiosis” by “antibacterial therapy”, “antibiogram” by “antibacteriogram”, and “antibiotic stewardship” by “antibacterial stewardship” (Seifert and Schirmer Trends Microbiol, 2021). In the present article, we show that many traditional terms related to antibiotics are used much more widely in the biomedical literature than the respective scientifically precise terms. This practice should be stopped. Moreover, we provide arguments to end the use of other broadly used terms in the biomedical literature such as “narrow-spectrum antibiotics” and “reserve antibiotics”, “chemotherapeutics”, and “tuberculostatics”. Finally, we provide several examples showing that antibacterial drugs are used for non-antibacterial indications and that some non-antibacterial drugs are used for antibacterial indications now. Thus, the increasing importance of drug repurposing renders it important to drop short designations of drug classes such as “antibiotics”. Rather, the term “drug” should be explicitly used, facilitating the inclusion of newly emerging indications such as antipsychotic and anti-inflammatory. This article is part of an effort to implement a new rational nomenclature of drug classes across the entire field of pharmacology.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Why the term “antibiotic” is problematic
Literally, the term “antibiotic” means “directed against life”. However, in reality, antibiotics designate drugs directed against bacteria. But, in fact, antibiotics are still both prescribed by professionals and expected by patients for treatment of non-bacterial diseases, most notably virus-caused diseases such as acute respiratory infections (Dhingra et al. 2020; Ray et al. 2019). The broad use of antibiotics in general medicine against “flu-like” diseases of the upper respiratory tract is a particularly bad example for overprescription of antibiotics (Fleming-Dutra et al. 2016; McDonagh et al. 2018). This misuse of antibiotics is a consequence of numerous interconnected factors, including misconceptions about the indication of antibiotics, intercollegial dynamics, patient expectations, and normative beliefs (Akkerman et al. 2005; Faure et al. 2009; Warreman et al. 2019). It can be hypothesized that the use of the historic misnomer “antibiotic” contributes to each of these factors. Because the socio-cultural/psycho-social research on the determinants of antibiotic resistance development is a quite young discipline, further research is needed to firmly establish such a contribution of imprecise terminology (Donisi et al. 2019). Regardless of the causes of misuse of antibacterial drugs, their inappropriate use has resulted in the emergence of numerous resistant bacterial strains including multi-resistant (or methicillin-resistant) Staphylococcus aureus (MRSA). These bacterial strains cause serious hospital-acquired infections and have led to the closure of whole wards (Curtis et al. 2019; Wu et al. 2019; Oliver et al. 2020; Zhao et al. 2020). Knowledge-based and psycho-social intervention programs targeting prescribers, “consumers”, and pharmacists have proven beneficial in reducing misuse of antibacterial drugs (Altiner et al. 2007; Burstein et al. 2019; Hickman et al. 2003). The use of precise terms in such interventions might help to clearly and unequivocally define the problems and challenges of antibacterial stewardship and prevention of emerging resistances.
Based on this linguistically and medically inacceptable situation, we have recently proposed to replace the term “antibiotics” by the term “antibacterial drugs” (Seifert and Schirmer 2021). This proposed change in nomenclature is actually consistent with the well-established use of the terms “bacteriostatic drugs” and “bactericidal drugs”. Related to this change in nomenclature, the term “antibiosis” should be replaced by “antibacterial therapy”, “antibiogram” by “antibacteriogram”, “antimicrobial” by “antipathogenic drug”, “antibiotic agents” by “antibacterial drugs”, “antibiotic activity” by “antibacterial potency”, and “antibiotic stewardship” by “antibacterial stewardship”. Table 1 provides the definitions of some important pharmacological terms in the field of antibacterial and antipathogenic therapy.
Problematic traditional terms are deeply rooted in the biomedical literature
To assess how often traditional terms are used in the biomedical literature, we analyzed scientific articles indexed in PubMed and compared the citation frequency of traditional (imprecise) terms versus that of scientifically precise terms (Fig. 1). It is quite astonishing that the imprecise term “antibiotics” is used 50 times more often than the precise term “antibacterial drug” (compare Fig. 1a versus Fig. 1b). This discrepancy is an indication that convention rather than critical reflection determines the use of this term in scientific literature. However, the imprecise term “antibiosis” and the precise term “antibacterial therapy” (compare Fig. 1c and d) are used with similar frequency which is inconsistent to the comparisons shown in Fig. 1a and b. Thus, as previously discussed for the terms “bactericidal” and “bacteriostatic”, precise terms are not necessarily ignored in the literature. Most strikingly, the imprecise term “antibiogram” (derived from “antibiotic”) is very broadly used in the literature, even with increasing frequency, whereas the precise term “antibacteriogram” was not found in a single PubMed-indexed publication under our search conditions at all (Fig. 1e versus Fig. 1f). In fact, even a non-confined Google search with the term “antibacteriogram” currently yields only ~ 60 hits (search date May 14, 2021).
The diffusely defined term “antimicrobials” is also excessively used in the literature, while the precise term “antipathogenic drugs” is rather uncommon (compare Fig. 1g and h). The historic term “agent”, which is poorly defined pharmacologically, is also deeply rooted in the biomedical literature although the precise term “antibacterial drug” has become more prevalent in recent years (compare Fig. 1i and j).
As stated recently, the term “activity” should be reserved to receptor agonists possessing intrinsic activity and stabilizing a pharmacologically active receptor conformation. Most antibiotic “agents” are actually enzyme inhibitors and not receptor agonists. Nonetheless, the imprecise term “antibiotic activity” is used far more commonly in the literature than the term “antibacterial potency” (compare Fig.1k and l).
As a result of improper and unreflective use of antibacterial drugs and the emergence of bacterial resistances, the biomedical field of antibacterial stewardship was developed to improve the rational use of these drugs in the clinics and fight development of bacterial resistances (Ha et al. 2019). Ironically, these important measures to improve proper use of antibacterial drugs have not yet penetrated scientific language. The imprecise term “antibiotic stewardship” is used more than 100-fold more often than the precise term “antibacterial stewardship” (compare Fig. 1m and n). Taken together, these examples illustrate that imprecise language use in the field of antibacterial therapy is very common in the biomedical literature. This is, however, not a trivial issue because language also strongly influences and shapes thinking and decision processes (Mahon and Kemmerer 2020). In this regard, there is clearly much to be done in the scientific language.
It could be argued that abandoning traditional terms would render literature searches more difficult. We concur that for a transition period, this may be the case, but in the long run, there is no alternative to using the precise term because the dissociation between traditional terminology and actual scientific meaning has become too large over the past seven to eight decades. In the future, the gap between traditional terms and their precision will inevitably further increase. The increased length of the precise terms is a possible downside of our proposed nomenclature, and this may be suspected to complicate communication. But based on the practical experience of the authors using the adapted nomenclature in scientific articles, teaching texts, and lectures, this is rarely the case.
More problematic terms linger in the literature
Table 2 lists several problematic terms in the field of antibacterial therapy that should not be used anymore and provides reasons for avoiding them. Figure 2 illustrates the use of these problematic terms in the biomedical literature. One of the most widely used problematic terms is “broad-spectrum antibiotics”. In fact, with increasing resistance of bacteria against broad-spectrum antibiotics (antibacterial drugs), the term “broad-spectrum antibiotics” is used with increasing frequency (Fig.2b) as if increasing the use of an imprecise term would alleviate the medical problem. Unfortunately, the term “broad-spectrum antibiotics” is not precisely defined. Quite different definitions exist which drugs are included in this definition. In fact, the definition of the term varies greatly with respect to time and geographical location, reflecting the dynamic resistance situation of pathogenic bacteria (Curtis et al. 2019; Wu et al. 2019). The term “narrow-spectrum antibiotics” is similarly poorly defined as the “broad-spectrum antibiotics” but also used with increasing frequency in the biomedical literature. In fact, due to the uncritical use of broad-spectrum antibiotics, several of these drugs have been converted to narrow-spectrum antibiotics meanwhile (Karam et al. 2016; Vivas et al. 2019). Related to the latter two terms, the term “reserve antibiotics” is used in the literature (Fig.2c), but due to their uncritical use, many reserve antibiotics have lost this status now, leaving us empty-handed without therapeutic alternatives (Remschmidt et al. 2017; Richter et al. 2019; Annamalai et al. 2021).
One of the most widely used terms in the field of antibacterial therapy is “chemotherapeutics”, and its use in the biomedical literature increases (Fig. 1d). Again, the term lacks an unequivocal definition. Historically, the term was initially coined to describe chemically synthesized antibacterial drugs (as opposed to naturally occurring antibiotics). Later, both natural and chemically synthesized antibacterial drugs were included in this category. Subsequently, the chemically synthesized cytostatic drugs with anti-tumor effects were included in this broad category as well. However, nowadays, in the general medical communication and in the media (TV, radio, Internet), the term chemotherapy is almost exclusively used to describe an anti-tumor therapy with cytostatic drugs. Moreover, the syllable “chemo” has a negative connotation of “bad” and “many side effects” (adverse drug reactions, ADR) as opposed to the syllable “bio”, implicating beneficial effects without harmful side effects (Wakiuchi et al. 2019; Ihrig et al. 2020). However, these associations are completely wrong.
Another popular term in the biomedical literature is “tuberculostatics” (Fig. 2e). This term alludes to the fact that these drugs inhibit the growth of Mycobacterium tuberculosis. However, in the biomedical literature, this term is also incorrectly used to include tuberculocidal drugs (Damasceno Junior et al. 2020; García-Caballero et al. 2020). Therefore, the precise terms “tuberculostatic drugs” and “tuberculocidal drugs” should be used. Similar considerations apply to the infrequently used term “leprostatics” including both “leprostatic drugs” and “leprocidal drugs” (Caliskan et al. 2019).
Like the term “chemotherapeutics”, the term “antimicrobial drugs” is not clearly defined, but nevertheless widely used in the literature. In fact, with the advent of drug repurposing, i.e., the use of old drugs for new therapeutic purposes, several traditional antibacterial (antipathogenic) drugs are now used for indications unrelated to bacterial diseases (Table 3). Conversely, many drugs traditionally used for the treatment of diseases unrelated to pathogen-caused diseases are now being repurposed for the treatment of pathogen-caused diseases (Table 4). This development has resulted in the term “non-antimicrobial drugs”. However, this term is a negative definition without a common mechanism of action or chemical structure. Therefore, the term “non-antimicrobial drugs” should not be used anymore, like the “non-opioid analgesics”, also including mechanistically heterogenous classes of drugs with diverse mechanisms of action. The nomenclature problem becomes even more evident considering the traditional and non-traditional designations of drug classes in the context of new indications (Tables 3 and 4).
These few examples highlight that the field of antibacterial (antipathogenic) drug therapy is abound with highly problematic terms that may deteriorate the precision of drug therapy, cause confusion, render literature searches increasingly difficult, and hinder patient communication. The eminent presence of problematic terms in the biomedical literature reflects the fact that authors, journal editors, and peer reviewers alike are not yet sufficiently aware of the issue and/or do not act accordingly.
First simple steps to improve terminology
Many traditional terms in the field of (antibacterial) drug therapy have become highly problematic. Particularly problematic is the use of the common prefix “anti” followed by a brief description of the drug class such as “antibiotics”. A simple immediate solution to the problem is to rigorously avoid all problematic terms, even if they have a long history, and rather use precise terms that do not bear the risk of confusion. As the most important example, instead of using the term “antibiotics”, the term “antibacterial drugs” should be used. The apposition of the simple word “drug” to a given drug class renders the term more precise, because this opens up the possibility that an antibacterial drug also possesses, e.g., antidepressive or antipsychotic effects (example of tetracyclines, Table 3). Conversely, the use of the term “anti-inflammatory drug” also leaves open the possibility that this drug additionally exhibits antibacterial effects (example of diflunisal and piroxicam, Table 4).
The process of abandoning the traditional drug nomenclature, highlighted by the case of antibiotics, will not only be important for pharmacology textbooks, the biomedical literature, and professional communication, but also for physician–patient communication. How should a patient understand that the doctor is prescribing an antibiotic for depression or schizophrenia? As a first step towards solving the problems associated with the use of traditional drug nomenclature in the public, one of the authors of this article has recently published a book in German language for a general audience explaining these problems (Seifert 2021). As the next step, the book will be adapted into English language for an international general audience.
What else needs to be done in the future
How will the revised nomenclature be viewed by international learned societies? Implementation and acceptance of the proposal will require endorsement by international learned societies. First of all, the drug nomenclature proposal will be discussed by the International Union of Basic and Clinical Pharmacology (IUPHAR). Similarly, the proposal must be discussed and approved by the International Union of Microbiological Societies (IUMS).
How will the nomenclature be integrated in textbooks and teaching? A textbook in English language has partially implemented some of the aspects discussed in this article (Seifert 2019). The textbook in German language (Roland Seifert, Basiswissen Pharmakologie (German language), second edition, Springer, 2021) has already fully implemented the proposed new nomenclature. The Federal Institute for Medical and Pharmaceutical Exam Questions (IMPP) in Germany has adopted the new nomenclature as well (https://www.impp.de/pruefungen/allgemein/gegenstandskataloge.html, accessed on May 14, 2021). Hence, the next generation of physicians in Germany will be familiar with the new nomenclature. The modern nomenclature facilitates learning, and students embrace the new nomenclature because of its logic. It will be more challenging for professors and lecturers to switch to the new nomenclature.
How will the nomenclature be implemented in the scientific literature? The traditional nomenclature renders literature searches extremely difficult and biased. The historic scientific track record cannot be changed anymore, but journal editors can gradually implement new nomenclature by amending the instructions for authors. But again, this change will require time because of the large number and heterogeneity of scientific journals.
How will the nomenclature be integrated into daily scientific communication? This issue probably represents the biggest hurdle because all scientists were socialized with the traditional nomenclature without even reflecting its problems.
Summary
Resistance against antibacterial drugs has become a major problem because of uncritical use of these drugs. Drug repurposing in the field of antipathogenic drugs becomes more important. Antipathogenic drugs are used for indications beyond pathogen-caused diseases, and drugs traditionally used in other fields are increasingly used for pathogen-caused diseases. Traditional terminology in the field of antipathogenic drugs is becoming increasingly imprecise. Terms such as “antibiotics”, “antibiogram”, “agent”, and “activity” should be dropped. A precise drug nomenclature based on chemical and mechanistic considerations is proposed. Terms such as “antibacterial drugs”, “antibacteriogram”, “drug”, and “potency” should be used instead of traditional terms. We are convinced that a precise terminology will improve the precision of science, assist reducing drug resistance, and improving antibacterial stewardship. To our knowledge, studies investigating the association between using correct medical terms and correct drug use are missing so far. Further research is needed to provide definitive evidence for this impact of using correct terms.
Data availability
The raw data of the literature search is amended to the main article as supplementary material (MS Excel data file).
Code availability
Not applicable.
References
Akkerman AE, Kuyvenhoven MM, van der Wouden JC, Verheij TJM (2005) Determinants of antibiotic overprescribing in respiratory tract infections in general practice. J Antimicrob Chemother 56(5):930–936. https://doi.org/10.1093/jac/dki283
Altiner A, Brockmann S, Sielk M et al (2007) Reducing antibiotic prescriptions for acute cough by motivating GPs to change their attitudes to communication and empowering patients: a cluster-randomized intervention study. J Antimicrob Chemother 60(3):638–644. https://doi.org/10.1093/jac/dkm254
Annamalai A, Gupta V, Jain S, Datta P (2021) Increasing resistance to reserve antibiotics: the experience of a tertiary level neonatal intensive care unit. J Trop Pediatr 67.https://doi.org/10.1093/tropej/fmaa086
Antoszczak M, Markowska A, Markowska J, Huczyński A (2020) Old wine in new bottles: drug repurposing in oncology. Eur J Pharmacol 866:172784. https://doi.org/10.1016/j.ejphar.2019.172784
Ben-Azu B, Omogbiya IA, Aderibigbe AO et al (2018) Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways. Brain Res Bull 139:114–124. https://doi.org/10.1016/j.brainresbull.2018.02.007
Burstein VR, Trajano R, Kravitz RL et al (2019) Communication interventions to promote the public’s awareness of antibiotics: a systematic review. BMC Public Health 19:899. https://doi.org/10.1186/s12889-019-7258-3
Butts A, Koselny K, Chabrier-Roselló Y, Semighini CP, Brown JC, Wang X, Annadurai S, DiDone L, Tabroff J, Childers WE Jr, Abou-Gharbia M, Wellington M, Cardenas ME, Madhani HD, Heitman J, Krysan DJ (2014) Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. MBio 5.https://doi.org/10.1128/mBio.00765-13
Caliskan Y, Dalgic AD, Gerekci S et al (2019) A new therapeutic combination for osteosarcoma: gemcitabine and clofazimine co-loaded liposomal formulation. Int J Pharm 557:97–104. https://doi.org/10.1016/j.ijpharm.2018.12.041
Carta D, Brun P, Dal Pra M et al (2018) Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs. Medchemcomm 9:1017–1032. https://doi.org/10.1039/c8md00139a
Curtis HJ, Walker AJ, Mahtani KR, Goldacre B (2019) Time trends and geographical variation in prescribing of antibiotics in England 1998–2017. J Antimicrob Chemother 74:242–250. https://doi.org/10.1093/jac/dky377
Damasceno Junior E, De AJMF, Silva IDN et al (2020) Obtaining and applying nanohybrid palygorskite-rifampicin in the ph-responsive release of the tuberculostatic drug. Langmuir 36:10251–10269. https://doi.org/10.1021/acs.langmuir.0c01834
Dhingra S, Rahman NAA, Peile E et al (2020) Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. Front Public Health 8:535668. https://doi.org/10.3389/fpubh.2020.535668
Donisi V, Sibani M, Carrara E et al (2019) Emotional, cognitive and social factors of antimicrobial prescribing: can antimicrobial stewardship intervention be effective without addressing psycho-social factors? J Antimicrob Chemother 74(10):2844–2847. https://doi.org/10.1093/jac/dkz308
El-Sherbeni AA, El-Kadi AOS (2016) Repurposing resveratrol and fluconazole to modulate human cytochrome p450-mediated arachidonic acid metabolism. Mol Pharm 13:1278–1288. https://doi.org/10.1021/acs.molpharmaceut.5b00873
Faure H, Mahy S, Soudry A et al (2009) Déterminants de la prescription ou de la non-prescription d’antibiotiques en médecine générale. Med Mal Infect 39(9):714–721. https://doi.org/10.1016/j.medmal.2009.05.002
Feng H, Hu L, Zhu H et al (2020) Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent. Acta Pharm Sin B 10:434–446. https://doi.org/10.1016/j.apsb.2019.08.002
Fleming-Dutra KE, Hersh AL, Shapiro DJ et al (2016) Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010–2011. JAMA - J Am Med Assoc 315:1864–1873. https://doi.org/10.1001/jama.2016.4151
García-Caballero A, Navarro-San Francisco C, Martínez-García L et al (2020) Forty years of tuberculous meningitis: the new face of an old enemy. Int J Infect Dis 99:62–68. https://doi.org/10.1016/j.ijid.2020.07.041
Gerber JS, Ross RK, Bryan M et al (2017) Association of broad- vs narrow-spectrum antibiotics with treatment failure, adverse events, and quality of life in children with acute respiratory tract infections. JAMA - J Am Med Assoc 318:2325–2336. https://doi.org/10.1001/jama.2017.18715
González A, Casado J, Chueca E, Salillas S, Velázquez-Campoy A, Espinosa Angarica V, Bénejat L, Guignard J, Giese A, Sancho J, Lehours P, Lanas Á (2019) Repurposing dihydropyridines for treatment of helicobacter pylori infection. Pharmaceutics 11. https://doi.org/10.3390/pharmaceutics11120681
Gowri M, Jayashree B, Jeyakanthan J, Girija EK (2020) Sertraline as a promising antifungal agent: inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro. J Appl Microbiol 128:426–437. https://doi.org/10.1111/jam.14490
Ha DR, Haste NM, Gluckstein DP (2019) The role of antibiotic stewardship in promoting appropriate antibiotic use. Am J Lifestyle Med 13:376–383. https://doi.org/10.1177/1559827617700824
Hai TP, Van AD, Ngan NTT et al (2019) The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans. Mycoses 62:818–825. https://doi.org/10.1111/myc.12955
Hickman DE, Stebbins MR, Hanak JR, Guglielmo BJ (2003) Pharmacy-based intervention to reduce antibiotic use for acute bronchitis. Ann Pharmacother 37(2):187–191. https://doi.org/10.1177/106002800303700204
Honda M, Shirasaki T, Terashima T et al (2016) Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis 213:1096–1106. https://doi.org/10.1093/infdis/jiv572
Husain MI, Chaudhry IB, Husain N et al (2017) Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol 31:1166–1175. https://doi.org/10.1177/0269881117724352
Ihrig A, Richter J, Grüllich C et al (2020) Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. J Cancer Res Clin Oncol 146:3189–3198. https://doi.org/10.1007/s00432-020-03336-1
Issy AC, Pedrazzi JFC, van Oosten ABS et al (2020) Effects of doxycycline in Swiss mice predictive models of schizophrenia. Neurotox Res 38:1049–1060. https://doi.org/10.1007/s12640-020-00268-z
Jang HI, Eom YB (2020) Antibiofilm and antibacterial activities of repurposing auranofin against Bacteroides fragilis. Arch Microbiol 202:473–482. https://doi.org/10.1007/s00203-019-01764-3
Joyner KR, Walkerly A, Seidel K et al (2020) Comparison of narrow-versus broad-spectrum antibiotics in elderly patients with acute exacerbations of chronic obstructive pulmonary disease. J Pharm Pract. https://doi.org/10.1177/0897190020938190
Jun BY, Choi MG, Lee JY et al (2014) Premedication with erythromycin improves endoscopic visualization of the gastric mucosa in patients with subtotal gastrectomy: a prospective, randomized, controlled trial. Surg Endosc 28:1641–1647. https://doi.org/10.1007/s00464-013-3364-y
Kandhi S, Zhang B, Froogh G et al (2017) EETs promote hypoxic pulmonary vasoconstriction via constrictor prostanoids. Am J Physiol - Lung Cell Mol Physiol 313:L350–L359. https://doi.org/10.1152/ajplung.00038.2017
Kapoor Y, Sharma R, Kumar A (2018) Repurposing of existing drugs for the bacterial infections: an in silico and in vitro study. Infect Disord - Drug Targets 20:182–197. https://doi.org/10.2174/1871526519666181126094244
Karam G, Chastre J, Wilcox MH, Vincent JL (2016) Antibiotic strategies in the era of multidrug resistance. Crit Care 20. https://doi.org/10.1186/s13054-016-1320-7
Kathwate GH, Shinde RB, Karuppayil SM (2015) Antiepileptic drugs inhibit growth, dimorphism, and biofilm mode of growth in human pathogen Candida albicans. Assay Drug Dev Technol 13:307–312. https://doi.org/10.1089/adt.2015.29007.ghkdrrr
Kumar R, Kolloli A, Singh P, Vinnard C, Kaplan G, Subbian S (2020) Thalidomide and phosphodiesterase 4 inhibitors as host directed therapeutics for tuberculous meningitis: insights from the rabbit model. Front Cell Infect Microbiol 9. https://doi.org/10.3389/fcimb.2019.00450
Layeghi-Ghalehsoukhteh S, Pal Choudhuri S, Ocal O, Zolghadri Y, Pashkov V, Niederstrasser H, Posner BA, Kantheti HS, Azevedo-Pouly AC, Huang H, Girard L, MacDonald RJ, Brekken RA, Wilkie TM (2020) Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Sci Rep 10. https://doi.org/10.1038/s41598-020-77373-8
Macreadie IG, Johnson G, Schlosser T, Macreadie PI (2006) Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol Lett 262:9–13. https://doi.org/10.1111/j.1574-6968.2006.00370.x
Mahon BZ, Kemmerer D (2020) Interactions between language, thought, and perception: cognitive and neural perspectives. Cogn Neuropsychol 37:235–240. https://doi.org/10.1080/02643294.2020.1829578
Martínez-Flórez A, Galizzi M, Izquierdo L et al (2020) Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases. Int J Parasitol Drugs Drug Resist 14:17–27. https://doi.org/10.1016/j.ijpddr.2020.07.002
McDonagh MS, Peterson K, Winthrop K et al (2018) Interventions to reduce inappropriate prescribing of antibiotics for acute respiratory tract infections: summary and update of a systematic review. J Int Med Res 46:3337–3357. https://doi.org/10.1177/0300060518782519
Mulder M, Radjabzadeh D, Kiefte-de Jong JC, Uitterlinden AG, Kraaij R, Stricker BH, Verbon A (2020) Long-term effects of antimicrobial drugs on the composition of the human gut microbiota. Gut Microbes 12. https://doi.org/10.1080/19490976.2020.1791677
Muthu D, Gowri M, Suresh Kumar G et al (2019) Repurposing of antidepression drug sertraline for antimicrobial activity against Staphylococcus aureus: a potential approach for the treatment of osteomyelitis. New J Chem 43:5315. https://doi.org/10.1039/c8nj06297h
Nandi S, Kumar M, Saxena M, Saxena AK (2020) The antiviral and antimalarial drug repurposing in quest of chemotherapeutics to combat COVID-19 utilizing structure-based molecular docking. Comb Chem High Throughput Screen 23. https://doi.org/10.2174/1386207323999200824115536
Ogundeji AO, Pohl CH, Sebolai OM (2016) Repurposing of aspirin and ibuprofen as candidate anti-Cryptococcus drugs. Antimicrob Agents Chemother 60:4799–4808. https://doi.org/10.1128/AAC.02810-15
Oliver JP, Gooch CA, Lansing S et al (2020) Invited review: fate of antibiotic residues, antibiotic-resistant bacteria, and antibiotic resistance genes in US dairy manure management systems. J Dairy Sci 103:1051–1071. https://doi.org/10.3168/jds.2019-16778
Pereira SG, Domingues VS, Theriága J et al (2018) Non-antimicrobial drugs: etodolac as a possible antimicrobial or adjuvant agent against ESKAPE pathogens. Open Microbiol J 12:288–296. https://doi.org/10.2174/1874285801812010288
Phanchana M, Phetruen T, Harnvoravongchai P, Raksat P, Ounjai P, Chankhamhaengdecha S, Janvilisri T (2020) Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile. Sci Rep 10. https://doi.org/10.1038/s41598-020-63199-x
Potula HHSK, Shahryari J, Inayathullah M et al (2020) Repurposing disulfiram (Tetraethylthiuram disulfide) as a potential drug candidate against borrelia burgdorferi in vitro and in vivo. Antibiotics 9:1–22. https://doi.org/10.3390/antibiotics9090633
Pryor R, Cabreiro F (2015) Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J 471:307–322. https://doi.org/10.1042/BJ20150497
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF (2015) Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23:231–269. https://doi.org/10.1007/s10787-015-0239-y
Ray MJ, Tallman GB, Bearden DT et al (2019) Antibiotic prescribing without documented indication in ambulatory care clinics: national cross sectional study. BMJ 367:l6461. https://doi.org/10.1136/bmj.l6461
Reijnders TDY, Saris A, Schultz MJ, van der Poll T (2020) Immunomodulation by macrolides: therapeutic potential for critical care. Lancet Respir Med 8:619–630. https://doi.org/10.1016/S2213-2600(20)30080-1
Remschmidt C, Schneider S, Meyer E et al (2017) Surveillance of antibiotic use and resistance in intensive care units (SARI) a 15-year cohort study. Dtsch Arztebl Int 114:858–865. https://doi.org/10.3238/arztebl.2017.0858
Richter DC, Brenner T, Brinkmann A et al (2019) New antibiotics for severe infections due to multidrug-resistant pathogens: definitive treatment and escalation. Anaesthesist 68:785–800. https://doi.org/10.1007/s00101-019-00646-z
Robertson J, Iwamoto K, Hoxha I et al (2019) Antimicrobial medicines consumption in Eastern Europeand Central Asia – an updated cross-national study and assessment of quantitativemetrics for policy action. Front Pharmacol 9:12. https://doi.org/10.3389/fphar.2018.01156
Schmidtner AK, Slattery DA, Gläsner J, Hiergeist A, Gryksa K, Malik VA, Hellmann-Regen J, Heuser I, Baghai TC, Gessner A, Rupprecht R, Di Benedetto B, Neumann ID (2019) Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner. Transl Psychiatry 9. https://doi.org/10.1038/s41398-019-0556-9
Seifert R (2021) Medikamente leicht erklärt. Springer, Berlin
Seifert R (2019) Basic knowledge of pharmacology. Springer International Publishing, Basel
Seifert R, Schirmer B (2021) A case to stop the use of the term “antibiotics.” Trends Microbiol. https://doi.org/10.1016/j.tim.2021.03.017
She P, Zhou L, Li S, Liu Y, Xu L, Chen L, Luo Z, Wu Y (2019) Synergistic microbicidal effect of auranofin and antibiotics against planktonic and biofilm-encased S. aureus and E. faecalis. Front Microbiol 10. https://doi.org/10.3389/fmicb.2019.02453
Simões-Silva MR, De Araújo JS, Oliveira GM et al (2017) Drug repurposing strategy against Trypanosoma cruzi infection: in vitro and in vivo assessment of the activity of metronidazole in mono- and combined therapy. Biochem Pharmacol 145:46–53. https://doi.org/10.1016/j.bcp.2017.08.025
Socias SB, González-Lizárraga F, Avila CL et al (2018) Exploiting the therapeutic potential of ready-to-use drugs: repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Prog Neurobiol 162:17–36. https://doi.org/10.1016/j.pneurobio.2017.12.002
Sokol PA, Malott R, Riedel K, Eberl L (2007) Communication systems in the genus Burkholderia: global regulators and targets for novel antipathogenic drugs. Future Microbiol 2:555–563. https://doi.org/10.2217/17460913.2.5.555
Soo V, Kwan B, Quezada H et al (2016) Repurposing of anticancer drugs for the treatment of bacterial infections. Curr Top Med Chem 17:1157–1176. https://doi.org/10.2174/1568026616666160930131737
Ueno Y, Maruyama N, Kanno M et al (2009) Effect of propranolol on hyphae formation signal in Candida albicans. Biol Pharm Bull 32:129–131. https://doi.org/10.1248/bpb.32.129
Urquiza P, Laín A, Sanz-Parra A, Moreno J, Bernardo-Seisdedos G, Dubus P, González E, Gutiérrez-de-Juan V, García S, Eraña H, San Juan I, Macías I, Ben Bdira F, Pluta P, Ortega G, Oyarzábal J, González-Muñiz R, Rodríguez-Cuesta J, Anguita J, Díez E, Blouin JM, de Verneuil H, Mato JM, Richard E, Falcón-Pérez JM, Castilla J, Millet O (2018) Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. Sci Transl Med 10. https://doi.org/10.1126/scitranslmed.aat7467
Vivas R, Barbosa AAT, Dolabela SS, Jain S (2019) Multidrug-resistant bacteria and alternative methods to control them: an overview. Microb Drug Resist 25:890–908. https://doi.org/10.1089/mdr.2018.0319
Wakiuchi J, Marcon SS, Oliveira DC de, Sales CA (2019) Chemotherapy under the perspective of the person with cancer: a structural analysis. Texto e Context Enferm 28. https://doi.org/10.1590/1980-265x-tce-2018-0025
Walker SL, Balagon M, Darlong J, Doni SN, Hagge DA, Halwai V, John A, Lambert SM, Maghanoy A, Nery JA, Neupane KD, Nicholls PG, Pai VV, Parajuli P, Sales AM, Sarno E, Shah M, Tsegaye D, Lockwood DN (2015) ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema Nodosum Leprosum. PLoS Negl Trop Dis 9. https://doi.org/10.1371/journal.pntd.0004065
Warreman EB, Lambregts MMC, Wouters RHP et al (2019) Determinants of in-hospital antibiotic prescription behaviour: a systematic review and formation of a comprehensive framework. Clin Microbiol Infect 25(5):538–545. https://doi.org/10.1016/j.cmi.2018.09.006
Weeks JC, Roberts WM, Leasure C, Suzuki BM, Robinson KJ, Currey H, Wangchuk P, Eichenberger RM, Saxton AD, Bird TD, Kraemer BC, Loukas A, Hawdon JM, Caffrey CR, Liachko NF (2018) Sertraline, paroxetine, and chlorpromazine are rapidly acting anthelmintic drugs capable of clinical repurposing. Sci Rep 8. https://doi.org/10.1038/s41598-017-18457-w
Wu J, Su Y, Deng Y et al (2019) Spatial and temporal variation of antibiotic resistance in marine fish cage-culture area of Guangdong, China. Environ Pollut 246:463–471. https://doi.org/10.1016/j.envpol.2018.12.024
Yardley MM, Huynh N, Rodgers KE et al (2015) Oral delivery of ivermectin using a fast dissolving oral film: implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol 49:553–559. https://doi.org/10.1016/j.alcohol.2015.03.006
Yimer EM, Hishe HZ, Tuem KB (2019) Repurposing of the β-lactam antibiotic, ceftriaxone for neurological disorders: a review. Front Neurosci 13:2260–2271. https://doi.org/10.3389/fnins.2019.00236
Zhao F, Yang H, Bi D, Khaledi A, Qiao M (2020) A systematic review and meta-analysis of antibiotic resistance patterns, and the correlation between biofilm formation with virulence factors in uropathogenic E. coli isolated from urinary tract infections. Microb Pathog 144. https://doi.org/10.1016/j.micpath.2020.104196
Zimmermann P, Ziesenitz VC, Curtis N, Ritz N (2018) The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms. Front. Immunol. 9. https://doi.org/10.3389/fimmu.2018.00302
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
RS conceived the topic and scope of the review. RS and BS performed the literature search, analyzed the data, and contributed to drafting the manuscript. All authors read and approved the final manuscript. The authors declare that all data were generated in-house and that no paper mill was used.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Seifert, R., Schirmer, B. Problems associated with the use of the term “antibiotics”. Naunyn-Schmiedeberg's Arch Pharmacol 394, 2153–2166 (2021). https://doi.org/10.1007/s00210-021-02144-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-021-02144-9